The case for & against
Bull & Bear analysis
Bearish
Amedisys, Inc. (NASDAQ: AMED) is a leading provider of home health care and hospice services in the U.S., focused on delivering personalized care to patients in their homes. The company operates in a dynamic healthcare environment emphasizing integrated service solutions and strategic partnerships, particularly in the Medicare Advantage space. Amedisys aims to leverage its innovative care models to adapt to evolving patient needs and regulatory landscapes while navigating the complexities of home-based care delivery.
Bull says
- ↑Demand for home health peaked; 2022 revenue forecast $2.244–2.274B.
- ↑Medicare Advantage contracts now a major revenue driver via CVS-Aetna deals.
- ↑Contessa integration ups high-acuity admissions by 69%, expanding service mix.
- ↑Generated $133M operating cash flow in 2022, reflecting strong liquidity.
- ↑Home health quality star score 4.49 supports competitive moat.
- ↑High revenue per episode (+3.2% YoY) indicates strong reimbursement mix.
Bear says
- ↓Staffing shortages and high clinical turnover elevate labor costs.
- ↓CMS proposals threaten 4.2% reduction in home health reimbursements for 2023.
- ↓Contessa deal integration lags, underscoring reliance on M&A for growth.
- ↓Competition intensifies with rising Medicare Advantage penetration among peers.
- ↓Projected 2023 EBITDA of $230–240M signals margin contraction risk.
- ↓Declining Medicare fee-for-service usage may pressure revenue mix.
Investment themes with AMED
Demographics: Elderly Care↑ +0.43%
Services and products for aging population
ENSG · ACHC · SEM
Earnings Call · Q4 2021 · Mgmt. Guidance
Updated 09-06-2026neutral
Transcript signals
Bull points
- bullish about 2022, but I'd say most of that is what I described is why revenue is a little off at this point.
- bullish
- bullish about 2022, but I'd say most of that is what I described is why revenue is a little off at this point.
Bear points
- we probably missed opportunity. I think that's one issue. The second issue on the revenue difference is that this completing hospital-to-home through the Medicare Waiver Program, we've gotten a lot of that business, and that's really at a lower revenue kind of per episode, if you want to use that label on it, than a typical risk base.
- I still think that it will be challenging to hire enough and net enough new staff to fully meet the demand when you think about the demand that's moving into the home and what was accelerated with the pandemic.
- EPS decreased $0.16 to $5.95
Read full transcript analysis ›